Health Care Supplies

Cerus

Cerus released FY2026 Q1 earnings on April 30 After-Market EST, actual revenue USD 53.66 M (forecast USD 49.01 M), actual EPS USD -0.01 (forecast USD -0.04)

Cerus to Release FY2026 Q1 Earnings on April 30 After-Market EST, Forecast Revenue USD 51.18 M, EPS USD -0.04

Cerus released FY2025 Q4 earnings on March 2 After-Market (EST), actual revenue USD 57.75 M (forecast USD 59.31 M), actual EPS USD -0.0113 (forecast USD -0.0075)

Cerus released FY2025 Annual Earnings on March 2 After-Market EST, actual revenue USD 206.13 M (forecast USD 221.57 M), actual EPS USD -0.0819 (forecast USD -0.08)

Cerus to Release FY2025 Q4 Earnings on March 2, After-Market EST; Forecast Revenue USD 59.31 M, EPS USD -0.0075

Cerus Corporation Signs Group Procurement Agreement with American Red Cross to Promote INTERCEPT Product Line

Cerus released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 52.7 M (forecast USD 55.12 M), actual EPS USD 0 (forecast USD -0.0275)

Cerus released FY2025 9 Months earnings on November 6 After-Market EST, actual revenue USD 148.38 M, actual EPS USD -0.0711

Cerus to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 55.12 M, EPS USD -0.0275

Cerus released FY2025 Semi-Annual earnings on August 5 After-Market (EST), actual revenue USD 95.68 M, actual EPS USD -0.0709

Cerus released FY2025 Q2 earnings on August 5 After-Market EST, actual revenue USD 52.45 M (forecast USD 51.8 M), actual EPS USD -0.0298 (forecast USD -0.0275)

Cerus to Release FY2025 Q2 Earnings on August 5 After-Market (EST), Forecast Revenue USD 51.8 M, EPS USD -0.0275

Cerus Corporation INT200 Receives Regulatory Approval in France and Switzerland

Cerus released FY2025 Q1 earnings on May 1 After-Market EST, actual revenue USD 43.24 M (forecast USD 47.44 M), actual EPS USD -0.0412 (forecast USD -0.04)

Cerus Corporation Reports Q1 2025 Financials

Cerus Corp to Report a Loss of 4 Cents Per Share

Cerus Announces Q1 2025 Earnings Preview and Insider Trading

Cerus to Release FY2025 Q1 Earnings on May 1 After-Market EST, Forecast Revenue USD 47.44 M, EPS USD -0.04

Cerus released FY2024 annual earnings on February 20 After-Market (EST), actual revenue 180.27 M USD (forecast 193.74 M USD), actual EPS -0.1133 USD (forecast -0.112 USD)

Cerus released FY2024 Q4 earnings on February 20 After-Market (EST), actual revenue $50.81M (forecast $52.95M), actual EPS -$0.0135 (forecast -$0.012)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

APLS

CERS

AVNS

Three healthcare stocks, Avanos Medical (AVNS), Apellis Pharmaceuticals (APLS), and Cerus Corp (CERS), are showing signs of being overbought, with RSI values of 90, 86.8, and 86 respectively. AVNS has gained 78% recently due to a going-private deal, APLS surged 100% following an acquisition announcement by Biogen, and CERS reported strong Q1 results, raising its sales guidance. Investors should be cautious as these stocks may face a downturn.

benzinga_article

Apellis Pharma

Avanos Medical

Health Care Select Sector SPDR

SPDR S&P Biotech

VG Health

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Biogen

Top 3 Health Care Stocks That May Collapse This Month

Cerus Corporation's Q1 earnings call highlighted strong revenue growth, with product revenue up 24% year-over-year to $53.7 million. The company raised its 2026 revenue guidance to $227–$231 million, indicating continued expansion. Despite a narrowed GAAP net loss of $1.6 million, gross margins fell to 52% due to rising costs. Management noted ongoing inflation and geopolitical risks as potential challenges. The platelet business drove North American growth, while international demand also contributed positively. Cerus aims for GAAP profitability as it advances regulatory milestones and maintains a solid cash position of $80.4 million.

Tip Ranks

Cerus Corporation Earnings Call Signals Profitable Growth

ESPR

TEAM

FIVN

WOLF

XNDU

TWLO

BAND

AXTI

SOUN

Esperion Therap(ESPR) rose 55.5%, with a trading turnover 569.3 Million USD, and a year-to-date fell 15.9%. Cerus(CERS) rose 33.99%, with a trading turnover 68.9 Million USD, and a year-to-date rose 32%. Atlassian(TEAM) rose 29.58%, with a trading turnover 2.4 Billion USD, and a year-to-date fell 45.2%.

Top Gainers&Losers

Esperion Therap

Atlassian

Five9

Wolfspeed

Xanadu Quantum Tech - B

Twilio

Bandwidth

SoundHound AI

Top 10 US Stock Gainers (5.1)

Cerus (NASDAQ:CERS) reported quarterly earnings of ($0.01) EPS, exceeding estimates by $0.02. Revenue reached $59.89 million, surpassing the $55.68 million forecast. The company raised its 2026 product revenue guidance to $227M–$231M. Despite a negative net margin of 7.58% and a return on equity of -26.09%, Cerus achieved a positive non-GAAP adjusted EBITDA of $4M. Shares rose 5.7% to $2.03. Insider selling occurred, with CFO Kevin Dennis Green selling 127,544 shares. Institutional investors have also adjusted their stakes in Cerus recently.

Market Beat

AllianceBernstein

Cerus (NASDAQ:CERS) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Cerus Corporation (NASDAQ:CERS) reported a 24% increase in Q1 2026 product revenue to $53.7 million, driven by strong performance in its global platelet franchise. The company raised its full-year revenue guidance to $227-$231 million and IFC revenue guidance to $22-$24 million. Cerus emphasized strategic initiatives for sustainable growth and highlighted progress in INTERCEPT technology adoption. Management expressed confidence in long-term growth potential and upcoming milestones for the Intercept Red Blood Cell program. The outlook includes expectations for positive adjusted EBITDA and a focus on achieving GAAP profitability.

Cerus Q1 2026 Earnings Call Transcript

Cerus Corp reported Q1 2026 results with revenue of $59.9M, a 23% increase year-over-year, and a narrowed net loss of $1.64M compared to $7.72M in Q1 2025. Diluted EPS was $(0.01). Revenue growth was driven by a 24% rise in product sales, particularly in disposable platelet kits. The company is shifting sales strategy towards IFC kits for blood centers. Operational challenges affected gross margins, and inventory was increased to meet demand. Regulatory progress includes advancements in red blood cell system development and contract revenue growth under BARDA agreements.

TradingView

Cerus Corp 1Q 2026: Revenue $59.9M, EPS $(0.01) — 10-Q Summary

Earnings Watch

Cerus | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 59.89 M

Cerus shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance.

Cerus(CERS.US)